• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Summit Therapeu ADR (NQ: SMMT )

    18.98 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Summit Therapeu ADR

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
    Via Benzinga
    Is Summit Therapeutics a Buy Now?
    The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
    Via The Motley Fool
    Why Summit Therapeutics Rocketed Over 60% Today
    The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market. 
    Via The Motley Fool
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
    Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%. 
    Via Investor's Business Daily
    Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
    Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,... 
    Via Benzinga
    Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024
    SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
    From Summit Therapeutics Inc.
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
    What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
    Via Investor's Business Daily
    Topics Government
    Exposures Political
    IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga
    Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Summit Therapeutics Inc.
    Via Business Wire
    7 Top Stocks Under $10: June 2024 Edition
    While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
    Via InvestorPlace
    3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
    These high-flying stocks could have more room to run if analysts are right. 
    Via The Motley Fool
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
    Via Talk Markets
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Why Summit Therapeutics Stock Is Trading 8% Higher Monday
    Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization. 
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
    From Summit Therapeutics Inc.
    Via Business Wire
    Day Trading During A Slow Holiday Week
    We made it to the end of a holiday-shortened week. It was a slow week of day trading, but I’m happy with how it finished. Let’s break it down in today’s recap. 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.